Tomas Freiberger received his degree from Masaryk University, Brno, Czech Republic in 1994.
He is a Professor of Medical Immunology, currently working as a Molecular Genetics Laboratory Director at the Centre for Cardiovascular Surgery and Transplantation in Brno, a principal investigator in the Medical Faculty of Masaryk University, and a clinical geneticist at the Prenatal diagnosis center. His research focuses on the genetic background of primary immunodeficiency and lipid metabolism disorders.
In the field of atherosclerosis, his work has been dedicated to familial hypercholesterolemia (FH) since 1998 when he founded and became responsible for the Czech MedPed (Make early diagnosis to prevent early deaths) initiative, establishing a network of 66 lipid centers all over the country and registering more than 9,500 FH patients. The project runs under the umbrella of the Czech Atherosclerosis Society, of which he is an Executive Committee member.
He is also a member of the Executive Committee of the European Atherosclerosis Society-driven FH Studies Collaboration, which is aiming more deeply to understand the contemporary FH burden, the Executive Committee of the Clinical Genome Resource FH Expert Panel, making efforts to provide an evidence-based interpretation of FH-associated genetic variants’ clinical importance to improve the care of FH patients, and the FH Europe Scientific Advisory Committee.
He supervises post-gradual students, has been a principal investigator of many research projects, including the National Institute for Research of Metabolic and Cardiovascular Diseases, and has authored a number of scientific papers in peer-reviewed journals.


Screening: experience from cascade screening, universal screening and latest insights on screening on the EU levelJoint FH Webinar series 2023: Let’s manage FH togetherWebinars on-demandCascade screening introduction and experience from Czech RepublicEAS AC on FH